FDA’s AI in Early Phase Clinical Trials RFI: An Opportunity to Help Set the Rules of the Road

Crowell & Moring LLP·May 11

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

The FDA is seeking input on the use of artificial intelligence in early phase clinical trials. A pilot program has been launched to explore the optimization of clinical trials using AI, although the objectives and details of the program are not entirely clear. The FDA's initiative may involve real-time clinical trial monitoring, but the specifics and potential risks of the program are still being discussed.

Full coverage

Accelerating and Modernizing Early and Late-Stage Clinical Development

fda.gov·Jun 22

FDA Requests Information on AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program

Office of Advocacy (.gov)·Apr 30

FDA asked to clarify AI pilot objectives for early-phase clinical trials

RAPS·Jul 1

AI Do: Why the FDA Wants Your Input on AI in Clinical Trials (and Why You Should Give It)

ArentFox Schiff·May 26

Fetching the latest headlines…

FDA’s AI in Early Phase Clinical Trials RFI: An Opportunity to Help Set the Rules of the Road

Full coverage

Accelerating and Modernizing Early and Late-Stage Clinical Development

FDA Requests Information on AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program

FDA asked to clarify AI pilot objectives for early-phase clinical trials

AI Do: Why the FDA Wants Your Input on AI in Clinical Trials (and Why You Should Give It)

FDA Launches Proof-of-Concept Real-Time Clinical Trials

5 Critical Risks With The FDA's Real-Time Trial Monitoring

FDA launches pilot for real-time clinical trials

Akin, an Elite Global Law Firm